MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.leukres.2025.107692

Медицинская библиотека · Leukemia research · 2025

Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome.

Braish Julie S, Montalban-Bravo Guillermo, Ravandi Farhad, Short Nicholas, Kadia Tapan, Ohanian Maro, Chien Kelly, Masarova Lucia, Sasaki Koji, Yilmaz Musa, Logahvi Sanam, Daver Naval, Borthakur Gautam, Jabbour Elias, Schneider Heather, Romero Lizabeth T, Kantarjian Hagop, Garcia-Manero Guillermo

СтатьяКлиническое исследование II фазыКлиническое исследование I фазыПеревод в очереди

Аннотация

OBJECTIVE

Therapies for patients with higher-risk myelodysplastic syndromes (HR-MDS) who have failed hypomethylating agents (HMAs) are needed. This Phase I/II study evaluates the safety, tolerability, and efficacy of venetoclax, an orally bioavailable BCL-2 inhibitor, in combination with azacitidine in this population.

METHODS

We conducted a single-center, dose-escalation, Phase I/II trial (NCT04550442) involving 33 patients with HR-MDS or CMML (IPSS ≥ 1.5) who had progressed after prior HMA therapy. Patients received intravenous or subcutaneous azacitidine (SC) (75 mg/m² for 5 days) and venetoclax (100-400 mg for 7-14 days in a 28-day cycle). The primary endpoints were safety/tolerability (Phase 1) and overall response rate (ORR) (Phase 2).

RESULTS

Patients received a median of 3 cycles (range, 1-22). The maximum tolerated dose of venetoclax was 400 mg. Common grade 3-4 adverse events included neutropenia (19 %) and thrombocytopenia (10 %). The 4-week early mortality rate was 9 %. The ORR was 49 %, and the median overall survival (OS) was 7 months (95 % CI, 3.5-10.5). The median progression-free survival (PFS) was 6 months (95 % CI, 3.0-9.0). Four patients (12 %) underwent stem cell transplantation, with 3 of 4 alive at last follow-up (75 %).

CONCLUSION

Combining venetoclax with azacitidine is feasible for HR-MDS and CMML patients who failed prior HMA therapy. However, this combination did not significantly improve clinical outcomes in this patient population.

Для цитирования: Braish Julie S, Montalban-Bravo Guillermo, Ravandi Farhad, Short Nicholas, Kadia Tapan, Ohanian Maro, Chien Kelly, Masarova Lucia, Sasaki Koji, Yilmaz Musa, Logahvi Sanam, Daver Naval, Borthakur Gautam, Jabbour Elias, Schneider Heather, Romero Lizabeth T, Kantarjian Hagop, Garcia-Manero Guillermo. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome.. Leukemia research. 2025. DOI: 10.1016/j.leukres.2025.107692.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.